Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
MENLO PARK, Calif., May 08, 2018 -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2018.
“We have undertaken additional efforts to aggressively manage our cash as we work diligently to complete our strategic review process,” said Jay Shepard, President and CEO of Versartis, Inc. “We acknowledge the patience our shareholders have shown during this process and we are committed to providing an update as soon as we can.”
First Quarter 2018 Financial Results
For the first quarter ended March 31, 2018, Versartis reported a net loss of approximately $9.0 million, or $0.25 per share, basic and diluted, compared to a net loss for the first quarter ended March 31, 2017 of $29.7 million, or $0.85 per share, basic and diluted.
Total operating expenses for the quarter ended March 31, 2018 were $8.5 million compared to $29.7 million for the quarter ended March 31, 2017. Research and development (R&D) expenses for the quarter ended March 31, 2018 were $3.6 million, compared to $22.0 million for the quarter ended March 31, 2017. The decrease in R&D expenses was primarily due to the termination of clinical and manufacturing related contracts that supported the company’s Phase 3 clinical trials for somavaratan following the Phase 3 VELOCITY trial failing to meet its primary endpoint.
General and administrative (G&A) expenses were $4.9 million for the quarter ended March 31, 2018 compared to $7.7 million for the quarter ended March 31, 2017. The decrease in G&A expenses was primarily due to the reduction in workforce and our continued efforts to reduce consulting and professional services expenses following the Phase 3 VELOCITY trial failing to meet its primary endpoint.
Total operating expenses for the quarter ended March 31, 2018 include non-cash stock-based compensation expense of $2.8 million compared to $3.9 million of non-cash stock-based compensation expense for the quarter ended March 31, 2017.
Cash, cash equivalents, and short-term investments were $74.7 million as of March 31, 2018.
Contacts:
Kevin Haas
VP, Finance
(650) 963-8595
[email protected]
Versartis, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share amounts)
| Three Months Ended | |||||||
| March 31, | |||||||
| 2018 | 2017 | ||||||
| Operating expenses | |||||||
| Research and development | $ | 3,600 | $ | 22,004 | |||
| General and administrative | 4,917 | 7,656 | |||||
| Total operating expenses | 8,517 | 29,660 | |||||
| Loss from operations | (8,517 | ) | (29,660 | ) | |||
| Interest income | 193 | 199 | |||||
| Other income (expense), net | (657 | ) | (261 | ) | |||
| Net loss | (8,981 | ) | (29,722 | ) | |||
| Net loss per share- basic and diluted | $ | (0.25 | ) | $ | (0.85 | ) | |
| Weighted-average common shares used to compute basic and diluted net loss per share | 36,019 | 35,004 | |||||
Versartis, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)
| March 31, | December 31, | ||||||
| 2018 | 2017 | ||||||
| Assets: | |||||||
| Cash and cash equivalents | $ | 74,686 | $ | 81,146 | |||
| Other assets | 3,594 | 3,743 | |||||
| Build-to-suit lease asset | 8,829 | 8,888 | |||||
| Total assets | $ | 87,109 | $ | 93,777 | |||
| Liabilities and stockholders' equity: | |||||||
| Accounts payable and other current liabilities | $ | 3,535 | $ | 5,593 | |||
| Build-to-suit lease obligation | 6,944 | 5,428 | |||||
| Total liabilities | 10,479 | 11,021 | |||||
| Total stockholders' equity | 76,630 | 82,756 | |||||
| Total liabilities and stockholders’ equity | $ | 87,109 | $ | 93,777 | |||
